DANIEL GLAZE to Treatment Outcome
This is a "connection" page, showing publications DANIEL GLAZE has written about Treatment Outcome.
Connection Strength
0.211
-
Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019 04 16; 92(16):e1912-e1925.
Score: 0.050
-
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Pediatr Neurol. 2017 Nov; 76:37-46.
Score: 0.044
-
A study of the treatment of Rett syndrome with folate and betaine. J Child Neurol. 2009 May; 24(5):551-6.
Score: 0.025
-
Spinal fluid 5-methyltetrahydrofolate levels are normal in Rett syndrome. Neurology. 2005 Jun 28; 64(12):2151-2.
Score: 0.019
-
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study. Med. 2024 Oct 11; 5(10):1275-1281.e2.
Score: 0.018
-
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study. Med. 2024 Sep 13; 5(9):1178-1189.e3.
Score: 0.018
-
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med. 2023 06; 29(6):1468-1475.
Score: 0.017
-
High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr. 1994 May; 124(5 Pt 1):803-6.
Score: 0.009
-
A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet A. 2011 Dec; 155A(12):2956-63.
Score: 0.007
-
Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006 Jun; 117(6):e1223-32.
Score: 0.005